Cirrito
John Cirrito, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20090035298 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER AMYLOID BETA ACCUMULATION ASSOCIATED DISORDERS - The present invention provides methods for treating amyloid-beta accumulation-associated disorders, such as Alzheimer's disease. The methods comprise modulating the concentration of amyloid-beta in the brain interstitial fluid. In particular, the methods comprise modulating the activity of corticotrophin-releasing factor (CRF), which in turn modulates the concentration of amyloid-beta. | 02-05-2009 |
John R. Cirrito, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20090264355 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER DISORDERS MEDIATED BY AMYLOID-BETA ACCUMULATION IN A SUBJECT - The invention provides methods of delaying the onset, slowing the progression, preventing, or treating Alzheimers disease in a subject. In particular, the invention provides methods of modulating transport of Aβ across the blood brain barrier of the subject. | 10-22-2009 |
Thomas P. Cirrito, New York, NY US
Patent application number | Description | Published |
---|---|---|
20080267947 | Cancer therapy with cantharidin and cantharidin analogs - Provided are methods for treating cancer in a patient, comprising administration of a therapeutically effective regimen of cantharidin or cantharidin analog of formula of formula I, II or III | 10-30-2008 |
Thomas P. Cirrito, Long Island City, NY US
Patent application number | Description | Published |
---|---|---|
20150079135 | METHODS FOR TREATING AND MONITORING THE STATUS OF CANCER - Provided herein are methods for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a peptide derived from the EphA2 protein and/or the IL-13Rα2 protein and monitoring the amount of cancer stem cells in said subject. Also provided herein are methods for monitoring the efficacy of an EphA2 peptide-based cancer treatment or an IL-13Rα2 peptide-based cancer treatment in a patient with cancer, comprising monitoring the amount of cancer stem cells in said subject prior to, during, and/or following cancer treatment of a patient. | 03-19-2015 |